212 related articles for article (PubMed ID: 8227490)
21. [Group psychotherapy in patients with panic disorder and agoraphobia].
Scheibe G; Albus M; Walther AU; Schmauss M
Psychother Psychosom Med Psychol; 1993 Jul; 43(7):238-44. PubMed ID: 8337352
[TBL] [Abstract][Full Text] [Related]
22. Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients.
Asnis GM; Hameedi FA; Goddard AW; Potkin SG; Black D; Jameel M; Desagani K; Woods SW
Psychiatry Res; 2001 Aug; 103(1):1-14. PubMed ID: 11472786
[TBL] [Abstract][Full Text] [Related]
23. A double-blind, placebo-controlled, multicenter study with alprazolam and extended-release alprazolam in the treatment of panic disorder.
Pecknold J; Luthe L; Munjack D; Alexander P
J Clin Psychopharmacol; 1994 Oct; 14(5):314-21. PubMed ID: 7806686
[TBL] [Abstract][Full Text] [Related]
24. Gepirone and the treatment of panic disorder: an open study.
Pecknold JC; Luthe L; Scott-Fleury MH; Jenkins S
J Clin Psychopharmacol; 1993 Apr; 13(2):145-9. PubMed ID: 8096526
[TBL] [Abstract][Full Text] [Related]
25. Psychopathology of panic attacks in panic disorder.
Uhlenhuth EH; Leon AC; Matuzas W
J Affect Disord; 2006 May; 92(1):55-62. PubMed ID: 16448702
[TBL] [Abstract][Full Text] [Related]
26. Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone.
de Beurs E; van Balkom AJ; Lange A; Koele P; van Dyck R
Am J Psychiatry; 1995 May; 152(5):683-91. PubMed ID: 7726307
[TBL] [Abstract][Full Text] [Related]
27. Panic disorder: treatment with valproate.
Woodman CL; Noyes R
J Clin Psychiatry; 1994 Apr; 55(4):134-6. PubMed ID: 8071256
[TBL] [Abstract][Full Text] [Related]
28. Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder.
Lydiard RB; Morton WA; Emmanuel NP; Zealberg JJ; Laraia MT; Stuart GW; O'Neil PM; Ballenger JC
Psychopharmacol Bull; 1993; 29(2):183-8. PubMed ID: 8290663
[TBL] [Abstract][Full Text] [Related]
29. Pharmacologic effect of toloxatone on reactivity to the 35% carbon dioxide challenge: a single-blind, random, placebo-controlled study.
Perna G; Cocchi S; Bertani A; Arancio C; Bellodi L
J Clin Psychopharmacol; 1994 Dec; 14(6):414-8. PubMed ID: 7884022
[TBL] [Abstract][Full Text] [Related]
30. A double-blind, randomised comparison of fluvoxamine with dothiepin in the treatment of depression in elderly patients.
Rahman MK; Akhtar MJ; Savla NC; Sharma RR; Kellett JM; Ashford JJ
Br J Clin Pract; 1991; 45(4):255-8. PubMed ID: 1810358
[TBL] [Abstract][Full Text] [Related]
31. Epidemiological data of patients treated with fluvoxamine: results from a 12 week non-comparative multicentre study.
Dewulf L; Hendrickx B; Lesaffre E
Int Clin Psychopharmacol; 1995 Jan; 9 Suppl 4():67-72. PubMed ID: 7622826
[TBL] [Abstract][Full Text] [Related]
32. Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder.
Nair NP; Bakish D; Saxena B; Amin M; Schwartz G; West TE
Anxiety; 1996; 2(4):192-8. PubMed ID: 9160622
[TBL] [Abstract][Full Text] [Related]
33. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group.
Michelson D; Lydiard RB; Pollack MH; Tamura RN; Hoog SL; Tepner R; Demitrack MA; Tollefson GD
Am J Psychiatry; 1998 Nov; 155(11):1570-7. PubMed ID: 9812120
[TBL] [Abstract][Full Text] [Related]
34. Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder.
Palatnik A; Frolov K; Fux M; Benjamin J
J Clin Psychopharmacol; 2001 Jun; 21(3):335-9. PubMed ID: 11386498
[TBL] [Abstract][Full Text] [Related]
35. Fluvoxamine attenuates panic induced by 35% CO2 challenge.
Pols HJ; Hauzer RC; Meijer JA; Verburg K; Griez EJ
J Clin Psychiatry; 1996 Nov; 57(11):539-42. PubMed ID: 8968304
[TBL] [Abstract][Full Text] [Related]
36. Do antidepressants selectively suppress spontaneous (unexpected) panic attacks? A replication.
Uhlenhuth EH; Matuzas W; Warner TD; Paine S; Lydiard RB; Pollack MH
J Clin Psychopharmacol; 2000 Dec; 20(6):622-7. PubMed ID: 11106133
[TBL] [Abstract][Full Text] [Related]
37. Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care.
Sharp DM; Power KG; Simpson RJ; Swanson V; Anstee JA
Br J Gen Pract; 1997 Mar; 47(416):150-5. PubMed ID: 9167318
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic efficacy assessment of weak variable magnetic fields with low value of induction in patients with drug-resistant depression.
Sobiś J; Jarzab M; Hese RT; Sieroń A; Zyss T; Gorczyca P; Gierlotka Z; Pudlo R; Matysiakiewicz J
J Affect Disord; 2010 Jun; 123(1-3):321-6. PubMed ID: 19896204
[TBL] [Abstract][Full Text] [Related]
39. Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine.
Sandmann J; Lörch B; Bandelow B; Härtter S; Winter P; Hiemke C; Benkert O
Pharmacopsychiatry; 1998 Jul; 31(4):117-21. PubMed ID: 9754844
[TBL] [Abstract][Full Text] [Related]
40. A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder.
Kramer MS; Cutler NR; Ballenger JC; Patterson WM; Mendels J; Chenault A; Shrivastava R; Matzura-Wolfe D; Lines C; Reines S
Biol Psychiatry; 1995 Apr; 37(7):462-6. PubMed ID: 7786960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
